Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Moderna’s recent recovery is welcome, but it also needs perspective. Even after the...
— Lawrence Burns / Paulina McPadden
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Moderna, Inc.
We first bought Moderna (MRNA) in April 2025, when investors were focused on the collapse in COVID vaccine revenue and its R&D cash burn. At our initial...
Moderna, a popular short position, was the main driver of sector performance. The shares rose...
Moderna, Inc. is a biotechnology company developing mRNA-based vaccines and therapeutics across infectious disease and oncology. Shares rose sharply...
More institutional theses from Baillie Gifford -International Concentrated Growth
This helps explain our ongoing interest in the semiconductor supply chain. TSMC’s advanced manufacturing,...
This helps explain our ongoing interest in the semiconductor supply chain. TSMC’s advanced manufacturing,...
This helps explain our ongoing interest in the semiconductor supply chain. TSMC’s advanced manufacturing,...